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Enhanced antiplatelet effect of enteric- 
-coated acetylsalicylic acid in  
co-administration with pantoprazole
AbstrAct
Background. Proton pump inhibitors (PPI) are recommended for patients receiving antiplatelet ther-
apy. Several studies have revealed that PPI may attenuate the antiplatelet effect of ASA. However, 
our pilot study has indicated a positive interaction between pantoprazole and enteric-coated aspirin. 
The aim of the current study was to confirm that pantoprazole enhances the antiplatelet effect of 
enteric-coated aspirin in patients with acute coronary syndrome (ACS) treated with dual antiplatelet 
therapy. Moreover, the influence of CYP2C19 polymorphism on the antiplatelet effect of aspirin 
was assessed.
Material and methods. Ninety three consecutive ACS patients were prospectively enrolled in a randomized, 
crossover, open-labeled study. Forty four patients were given orally 40 mg of pantoprazole for the initial four 
days while the remaining forty nine were treated with pantoprazole from the 5th to the 8th day of hospitaliza-
tion. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the 4th and 8th days 
of hospitalization. Aggregation in response to arachidonic acid was assessed by impedance aggregometry.
Results. Lower mean platelet aggregation on pantoprazole was observed on the 8th day of hospitalization 
(p = 0.03). A cross-time analysis of platelet aggregation demonstrated statistical significance at two hours 
and six hours after co-administration of pantoprazole and antiplatelet agents, with the highest absolute 
difference observed two hours after drugs ingestion.  No significant differences in aggregation between 
study groups were observed on the 4th day of hospitalization. No influence of CYP2C19 polymorphism 
on the antiplatelet effect of aspirin was observed.
Conclusions. Co-administration of pantoprazole enhances the antiplatelet effect of enteric-coated aspirin 
in patients with ACS. 
Key words: platelet aggregation, acetylsalicylic acid, pantoprazole, proton pump inhibitors, antiplatelet 
therapy, acute coronary syndrome
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Introduction
Platelet activation induced by atherothrombotic 
plaque rupture plays a crucial role in the pathology of 
acute vascular incidents [1]. For that reason, antiplatelet 
therapy remains the mainstay for the prevention and 
treatment of heart attack, stroke or acute limb ischaemia 
[1–3]. Aspirin (ASA, acetylsalicylic acid) is the oldest and 
most commonly used antiplatelet drug worldwide. On 
the basis of available data, the guidelines recommend 
an indefinite low oral dose of ASA for secondary pre-
vention of cardiovascular incidents [4]. 
Corresponding author: 
Michał Kasprzak, Department 
of Cardiology and Internal Medicine, 
Nicolaus Copernicus University, 
Collegium Medicum 
Sklodowskiej-Curie Street No 9, 
85–094 Bydgoszcz, Poland 
E-mail: medkas@tlen.pl
Folia Medica Copernicana 2013; 
Volume 1, Number 1, 5–11  
Copyright © 2013 Via Medica 
ISSN 2300–5432
6folia Medica copernicana 2013, vol. 1, no 1
www.fmc.viamedica.pl
Antiplatelet treatment with aspirin and P2Y12 re-
ceptor antagonists (ticlopidine, clopidogrel, prasugrel, 
ticagrelor) carries a substantial risk of gastrointestinal 
bleeding. For that reason, many patients requiring 
chronic dual antiplatelet therapy, especially those with 
high risk of gastrointestinal complications, additionally 
receive gastroprotective agents. 
Some earlier studies have indicated that proton 
pump inhibitors (PPI) may attenuate the antiplatelet and 
antipyretic activity of aspirin [5, 6]. Compatible results 
were recently obtained by Wurtz et al. in a retrospective 
case-control study [7]. However, our pilot study found 
a positive interaction between pantoprazole and enter-
ic-coated ASA [8]. Furthermore, PPI influence may be 
affected by genetic polymorphism of CYP2C19, as this 
is a principal enzyme in PPI metabolism.
The aim of the current study was to confirm that 
pantoprazole enhances the antiplatelet effect of enter-
ic-coated aspirin in patients with acute coronary syn-
drome treated with percutaneous coronary intervention 
and dual antiplatelet therapy. Moreover, the influence 
of CYP2C19 polymorphism on the antiplatelet effect of 
aspirin was assessed.
Methods
Patients 
Ninety three consecutive patients (68 men and 
25 postmenopausal women) admitted to the De-
partment of Cardiology and Internal Medicine of the 
Collegium Medicum in Bydgoszcz with a diagnosis of 
acute coronary syndrome (ACS) and designated to 
undergo percutaneous coronary intervention (PCI) were 
prospectively recruited in a randomized, crossover, 
open-labeled study.
Study design 
Patients were randomised to receive low-dose 
(75 mg) enteric-coated aspirin alone (49 patients) or 
in combination with pantoprazole 40 mg q.d. (44 pa-
tients) for four days, with a subsequent cross-over to 
receive the alternative treatment regimen for the next 
four days. Trial exclusion criteria included:
 — age less than 18 years;
 — clinical indications for PPI usage;
 — clinical indications for a prolonged use of heparin 
or fondaparinux;
 — clinical indications for ASA or clopidogrel maintain-
ing daily dose > 75 mg;
 — persistent atrial fibrillation or other indications for 
oral anticoagulants;
 — cardiogenic shock on admission or initiation of 
treatment with vasopressors before PCI;
 — a history of chronic heart failure in functional class III 
or IV according to the New York Heart Association 
(NYHA), haemodynamically significant valvular heart 
disease or idiopathic cardiomyopathy;
 — thrombocytopenia (< 100,000/mm3) or history of 
congenital or acquired bleeding disorder;
 — anaemia, defined as haemoglobin level < 10.0 g/dL
 — any symptomatic concomitant infection.
All participants provided an informed written consent 
before the study entry. The study protocol was approved 
by the Local Ethics Committee.
Concomitant pharmacotherapy
At the first contact with healthcare providers, im-
mediately after establishing the diagnosis of ACS and 
qualification for PCI, all patients were pre-treated with an 
intravenous bolus of unfractionated heparin (70 IU/kg, 
up to 5,000 IU) and oral loading doses of clopidogrel 
(600 mg) and aspirin (300 mg). At the catheterisation 
laboratory, a second dose of unfractionated heparin 
was administered intra-arterially in a weight-adjusted 
manner (up to 100 IU/kg) or under activated clotting 
time guidance (to the target range of 200–250 seconds), 
if abciximab, a blocker of platelet glycoprotein IIb/IIIa, 
was intended. Abciximab was given at the discretion of 
the invasive cardiologist. Throughout the hospitaliza-
tion, clopidogrel was continued in single daily doses 
of 75 mg given at 8.00 a.m. Post-discharge antiplatelet 
therapy was planned in accordance with the current 
European recommendations. Concomitant medications 
in all patients, including ramipril and bisoprolol, were 
administered at 8.00 a.m. in doses adjusted for resting 
heart rate and blood pressure, while atorvastatin was 
ingested at 8.00 p.m.
Measurement of platelet aggregation
Blood samples were collected into hirudin-con-
taining tubes at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 
7.00 p.m. on the 4th and 8th days of hospitalisation. 
The 4th day of hospitalization was chosen for blood 
sampling because at this time patients with acute 
coronary syndrome are usually mobile and leave the 
coronary care unit, and both aspirin and clopidogrel 
fully exert their antiplatelet properties. The 8th day (i.e. 
the fourth day after introducing pantoprazole therapy) 
was chosen because the four-day period has been 
assumed to be long enough to allow for interaction 
between pantoprazole and antiplatelet agents, if one 
existed. For patients admitted after 7.00 p.m., the next 
day was regarded as the first day of their hospital stay. 
Aggregation in whole blood was assessed within two 
hours of venipuncture on a Multiplate® device (Dy-
nabyte, Munich, Germany), as recommended by the 
manufacturer [9].
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PCI procedure and methodology of platelet aggre-
gation measurements were described previously [8]. 
cYP2c19 genotyping
Genomic DNA was extracted from whole blood sam-
ples according to standard procedures. CYP2C19*17 
(CYP2C19_-806_C>T, rs12248560) was genotyped 
with a commercially available assay (TaqMan Drug 
Metabolism Genotyping Assay C_469857_10, Ap-
plied Biosystems, Foster City, CA, USA) on an ABI 
Prism Sequence Detector 7000 (Applied Biosyste-
ms) according to the manufacturer’s instructions. 
CYP2C19*2 (CYP2C19_681_G>A; rs4244285) was 
genotyped with a real-time allelic discrimination assay 
on the same detector. Randomly selected samples were 
evaluated by direct sequencing of PCR (polymerase 
chain reaction) products using a BigDye Terminator 
v. 3.1 sequencing kit and a 3130xl Genetic Analyser 
(Applied Biosystems). Real-time discrimination and 
sequencing method gave consistent results. Carriers 
of loss of function CYP2C19*2 allele were classified 
as ‘poor metabolisers’, whereas patients with gain of 
function CYPC19*17 allele were classified as ‘ultra 
metabolisers’. CYP2C19*1 homozygotes were catego-
rised as normal and CYP2C19*2/*17 heterozygotes as 
mixed metabolisers.
Statistical analysis
Use of the Shapiro-Wilk test demonstrated that the 
investigated variables were not normally distributed. 
Therefore, continuous results were reported as median 
values and interquartile ranges. The Mann-Whitney U 
and Kruskal–Wallis tests were used to compare con-
tinuous variables between both study groups. For 
categorical variables, the χ2 test (with Yates correction 
if necessary) was used. A value of p < 0.05 was con-
sidered statistically significant. All computations were 
carried out with Statistica, version 10.0 (StatSoft, Tulsa, 
OK, USA).
results
Statistical analysis showed no significant differences 
in basic clinical, angiographic or procedural character-
istics between both groups. 
The comparison of arachidonic acid-dependent 
platelet aggregation measured on the 8th day of hos-
pitalization revealed statistically significant lower mean 
platelet aggregation in patients treated with pantopra-
zole (p = 0.03). This tendency was also preserved when 
aggregation of platelets was analysed separately at dif-
ferent time points. Statistical significance was reached Ta
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Figure 1. Comparison of arachidonic acid-dependent platelet aggregation on 8th day of hospitalization in patients on 
dual antiplatelet therapy treated with and without pantoprazole
Figure 2. Comparison of arachidonic acid-dependent platelet aggregation on 4th day of hospitalization in patients on 
dual antiplatelet therapy treated with and without pantoprazole 
for measurements obtained at 10.00 a.m. (two hours 
after morning ingestion of medications) (p = 0.02) and 
2.00 p.m. (six hours after morning ingestion of med-
ications) (p = 0.04). The highest absolute difference 
in arachidonic acid-dependent aggregation between 
patients treated with and without pantoprazole was 
observed at 10.00 a.m. (20 U vs. 11 U) (Tab. 1, Fig. 1).
In contrast, the comparison of platelet aggregation 
measured on the 4th day of hospitalization showed no signif-
icant differences between the study groups (Tab. 1, Fig. 2). 
Genetic analysis revealed no relationship between 
CYP2C19 gene polymorphism and the difference in 
arachidonic acid-dependent aggregation, either with 
or without pantoprazole (Tab. 2). 
Discussion
Co-administration of PPI is an effective way to pre-
vent gastrointestinal complications in patients receiving 
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Table 2. Comparison of mean arachidonic acid-dependent platelet aggregation without and with concomitant 
treatment with pantoprazole according to CYP2C19 gene polymorphism [median (lower quartile–upper quartile)]
Gene polymorphism
Platelet aggregation without 
pantoprazole
Platelet aggregation with 
pantoprazole p†
CYP2C19*1/*1
normal metaboliser 
n = 29
14 (11–22) 15.5 (9 –19) 0.60
CYP2C19*1/*2 or CYP2C19*2/*2
poor metabolizer n = 27
13 (8–22) 12 (5.5–17.5)
CYP2C19*1/*17 or
CYP2C19*17/*17
ultra metabolizer n = 27
16 (7.5–28) 15 (7–20.5)
CYP2C19*2/*17 mixed metaboliser
n = 6
14 (5–23) 12 (9–13)
† — p value for heterogeneity in difference between arachidonic acid-dependent aggregation with and without pantoprazole among different 
genotypes
antiplatelet therapy for the prevention of cardiovascular 
events [10, 11]. Enteric coating also seems to reduce 
adverse effects of ASA [12, 13], even though its pro-
tective effect remains uncertain [14]. On the other 
hand, drug interactions may have a significant impact 
on the effectiveness of therapy, especially in chronic 
conditions. Two large-scale studies have caused lively 
discussion and given rise to many experiments on the 
potential reduction of clopidogrel’s effectiveness by 
proton pump inhibitors [15, 16]. Although ASA usage 
is very common, the evidence regarding its interaction 
with gastroprotective agents remains insufficient. 
Our results confirmed the findings of our recently 
published pilot study which, to the best of our know ledge, 
was the first study showing enhanced effectiveness of 
ASA with the co-administration of antisecretory agents [9]. 
Previously conducted experimental studies and 
retrospective analyses have reported diminished effec-
tiveness of ASA in co-administration with antisecretory 
agents when a non-enteric-coated formulation of ASA 
was used [6–8]. Based on the results of our aforemen-
tioned study, the first to investigate the impact of PPI 
on the antiplatelet potency of enteric-coated aspirin, 
we proposed the influence of enteric coating as an 
explanation for the discrepancy between our results 
and other trials [9]. 
Another, similarly designed, cross-over study was 
published in 2009 by Adamopoulos et al. [17]. It ex-
amined the impact of lansoprazole on platelet aggre-
gation in 24 patients with arterial hypertension treated 
with a low daily dose (100 mg) of enteric-coated ASA 
for primary cardiovascular prevention. No significant 
differences in optical aggregometry, PFA-100 analyser 
measurements or salicylic acid plasma concentrations 
were found between the analysed groups. This data 
suggests that lansoprazole co-therapy does not affect 
the antiplatelet potency of the enteric-coated form of as-
pirin. However, it should be stressed that this study was 
conducted on a relatively small population of patients.
Our present research gave two distinct sets of re-
sults. While comparisons of platelets aggregation in the 
second set of measurements (the 8th day of hospitaliza-
tion) fully confirmed the findings from our pilot study, 
results from the first set of measurements (the 4th day 
of hospitalization) showed no significant interactions 
between pantoprazole and enteric-coated ASA.
In our pilot study, to explain the observed drug 
interaction, we suggested higher gastric pH due to 
concomitant pantoprazole treatment as the reason 
for enhanced bioavailability of enteric-coated ASA [8]. 
Plain aspirin is a weakly acidic drug which crosses the 
mucosa of the gastroduodenal epithelium in its lipophilic 
state. To a lesser extent, it is transported through the 
upper part of the intestine where it can be absorbed, in 
its ionised form, despite the alkaline environment [18]. 
Acid suppression diminishes the gastric absorption of 
aspirin because ASA is not absorbed in the stomach 
when its pH is above 6.5 [19]. For that reason, con-
comitant usage of PPIs or H2 receptor antagonists 
interferes with the therapeutic action of plain aspirin. 
Enteric-coated preparations are created to bypass the 
stomach and prescribed in an attempt to reduce gastro-
intestinal side effects. They deliver ASA into the neutral 
pH environment of the small intestine where absorption 
of aspirin is possible but considerably delayed, and 
where bioavailability is reduced [18, 20, 21]. Methacrylic 
acid, used to form the outer sheet of enteric-coated ASA, 
remains stable in acid solutions. Active substances are 
released when pH exceeds 5.5. In normal conditions, 
these drugs pass intact through the upper part of the 
gastrointestinal tract and do not release active sub-
stances unless they reach the duodenum or more distal 
parts of the intestine. The addition of PPI, by alkalising 
gastric pH, causes destabilisation of the methacrylic 
acid sheath in the stomach and, in consequence, rapid 
absorption with higher bioavailability.
This postulated mechanism seems to be support-
ed by the fact that, in both our studies, the highest 
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difference in medians of arachidonic acid-dependent 
platelet aggregation was found two hours after morning 
ingestion of the investigated drugs. 
Interestingly, our present study found no differences 
in platelet aggregation comparing results in the first 
set of measurements done on the 4th day after myo-
cardial infarction onset and PCI. Coronary angioplasty 
causes atherothrombotic plaque rupture, endothelial 
injury and arterial wall damage. These, in turn, en-
hance coagulation and the release of inflammatory and 
chemoattractant factors, which in consequence may 
activate platelets [22–25]. These phenomena provide 
an explanation of the results obtained by Siller-Matula 
et al. in a study assessing platelet function at different 
time points after PCI [26]. In this study, the antiplatelet 
effect of clopidogrel and aspirin was diminished im-
mediately post PCI. In the aforementioned studies, the 
proinflammatory and hypercoagulability state seemed 
to normalise within 24 hours. However, its influence on 
platelet function may, to some extent, persist for the 
whole platelet lifespan, which in normal conditions is 
up to ten days. 
It is important to stress that all patients in our study 
were pretreated with a loading dose of uncoated ASA 
once the diagnosis of ACS was established. Since 
ASA-induced platelet cyclooxygenase-1 (COX-1) inac-
tivation is irreversible, its restoration depends on new 
platelets being produced in the bone marrow. That is 
why, in physiological conditions, full COX-1 restoration 
may take up to ten days [27]. 
This means that both series of measurements 
performed in our study, particularly the first one from 
the 4th day of hospitalization, might have been influ-
enced by thrombogenic and proinflammatory factors 
released during ACS and PCI, or by the antiplatelet 
effect of the loading dose of ASA. These factors may 
have a stronger impact on platelet aggregation than 
the interaction with pantoprazole and this could be the 
reason for the lack of interaction observed in the first 
series of measurements.
All PPIs are extensively metabolised in the liver by 
cytochrome P450 enzymes CYP2C19 and CYP3A4. The 
main pathway of pantoprazole inactivation is demeth-
ylation, by CYP2C19 [28]. Gene polymorphism of that 
enzyme, by influencing the plasma concentration of 
pantoprazole, might also have an impact on interaction 
with enteric-coated ASA. However, our present study 
did not confirm a relationship between CYP2C19 gene 
polymorphism and the difference in arachidonic ac-
id-dependent aggregation with or without pantoprazole. 
The main limitation of our study is that we have not 
ultimately proven that the observed differences in plate-
let aggregation are due to changes in drug absorption 
in the digestive tract. Such confirmation may come from 
direct measurements of blood ASA concentrations. This 
would however be very difficult to perform as the plasma 
half-life of ASA is relatively short (about 15 minutes) 
because of rapid hydrolysation to salicylic acid in 
erythrocytes and the liver [23]. An indirect approach to 
support our theory might be the measurement of platelet 
aggregation one hour after drugs ingestion. 
Another limitation was the relatively short (four days) 
period with and without concomitant pantoprazole treat-
ment in our cross-over designed study. This enabled 
study completion during one hospital stay, assuring 
100% adherence to the therapy. On the other hand, it 
was probably the reason why no interaction between 
enteric-coated ASA and pantoprazole was seen in the 
first series of measurements. In this setting, an impact of 
the acute phase of ACS and ASA loading dose cannot 
be excluded. There was also no washout period after 
pantoprazole treatment in patients who received the 
drug in the first phase of the study. Therefore, perform-
ing a similar study but providing measurements later, 
after the onset of ACS together with proper washout 
periods, is worth consideration.
In conclusion, our study indicates that co-adminis-
tration of pantoprazole enhances the antiplatelet effect 
of enteric-coated aspirin in ACS patients
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